In light of Anavex Life Sciences’ promising drug candidate (ANAVEX3-71), coupled with Mission Therapeutics’ recent fundraising of £25.2 million to advance their mitophagy program (MTX325), there has been growing evidence of interest towards broader disease groups with underlying pathogenesis from mitochondrial dysfunction.

This November, we reunited 60+ C-Level, Biologist, Preclinical, Translational, and Innovation-Scouting Leaders who are building from the industry’s latest setbacks to innovate mitochondria-targeting approaches and expand novel therapeutic opportunities.

From cutting-edge research backed by academia to transformative pipeline updates from preclinical and clinical settings revealed by the industry, this was your chance to get involved and de-risk clinical development of patient-centered therapeutics through the discovery and validation of biomarkers for defined endpoints.